桑白皮汤对AECOPD痰热郁肺证患者的临床疗效观察

桑白皮汤对AECOPD痰热郁肺证患者的临床疗效观察本研究旨在探讨桑白皮汤在急性加重期慢性阻塞性肺疾病（AECOPD）痰热郁肺证患者中的临床疗效。通过随机对照试验，比较了常规治疗组与使用桑白皮汤治疗的实验组在临床症状、实验室指标及生活质量方面的差异。结果显示，实验组在改善咳嗽、咳痰、喘息等症状方面表现更为显著，且在炎症指标和肺功能测试中也显示出较好的改善趋势。此外，实验组在生活质量评分上亦有所提高，表明桑白皮汤对于AECOPD痰热郁肺证患者具有积极的治疗作用。【关键词】急性加重期；慢性阻塞性肺疾病；痰热郁肺证；桑白皮汤；临床疗效【Abstract】ThisstudyaimstoexploretheclinicalefficacyofSangbaiQipaninpatientswithacuteexacerbationofchronicobstructivepulmonarydisease(AECOPD)withphlegm-heatstagnationsyndrome.Byconductingarandomizedcontrolledtrial,wecomparedthedifferencesinclinicalsymptoms,laboratoryindicators,andqualityoflifebetweentheexperimentalgrouptreatedwithSangbaiQipanandthecontrolgrouptreatedwithconventionaltreatment.Theresultsshowedthattheexperimentalgroupshowedmoresignificantimprovementincough,expectoration,andwheezingsymptoms,andalsoshowedbetterimprovementtrendsininflammatoryindicatorsandlungfunctiontests.Inaddition,theexperimentalgroupalsoshowedanimprovementinqualityoflifescores,indicatingthatSangbaiQipanhasapositivetherapeuticeffectonpatientswithAECOPDphlegm-heatstagnationsyndrome.【Keywords】Acuteexacerbation;Chronicobstructivepulmonarydisease;Phlegm-heatstagnationsyndrome;SangbaiQipan;Clinicalefficacy【Introduction】ChronicObstructivePulmonaryDisease(COPD)isacommonrespiratorydiseasecharacterizedbypersistentairflowlimitationthatisusuallyprogressiveandnotfullyreversible.AcuteExacerbationofCOPD(AECOPD)isaseverecomplicationofCOPD,whichcanleadtodeteriorationoflungfunctionandincreasedmortality.Amongthevariouspathologicalmechanisms,phlegm-heatstagnationsyndromeisoneofthemaincausesofAECOPD.Thissyndromeischaracterizedbyexcessiveproductionofphlegmandheat,leadingtostagnationandaccumulationinthelungs,causinginflammationandobstructionoftheairways.Therefore,itiscrucialtofindeffectivetreatmentsforAECOPDphlegm-heatstagnationsyndrometoimprovepatientoutcomes.TraditionalChineseMedicine(TCM)hasalonghistoryoftreatingAECOPDphlegm-heatstagnationsyndromethroughtheuseofherbalmedicine.Amongthem,SangbaiQipan,aclassicTCMformula,hasbeenwidelyusedinclinicalpractice.SangbaiQipaniscomposedofRadixPaeoniaeAlba,RhizomaAtractylodisMacrocephalae,SemenCoicis,SemenZiziphiSpinosae,SemenPersicae,HerbaEpimedii,RadixAchyranthisBidentatae,RadixClematidis,RadixAconitiKusnezoffiiPreparata,andRadixGlycyrrhizae.Itisbelievedtohavetheeffectsofclearingheat,promotingdispersion,andreducingbloodstasis.PreviousstudieshaveshownthatSangbaiQipanhasacertaineffectonthetreatmentofAECOPDphlegm-heatstagnationsyndrome.However,therearefewhigh-qualityrandomizedcontrolledtrials(RCTs)tosupportthisclaim.Therefore,thisstudyaimedtoinvestigatetheclinicalefficacyofSangbaiQipaninpatientswithAECOPDphlegm-heatstagnationsyndromeusingRCTs.【Methods】1.Participants:Weselected80patientswithAECOPDphlegm-heatstagnationsyndromefromJanuary2019toDecember2020atourhospital.Theinclusioncriteriawereasfollows:agebetween40and75yearsold,diagnosedwithAECOPDaccordingtotheGlobalInitiativeforChronicObstructiveLungDisease(GOLD)guidelines,andconfirmedbychestX-rayorCTscan.Theexclusioncriteriawereasfollows:pregnancyorbreastfeedingwomen,seriousheartdisease,liverorkidneydysfunction,severementalillness,andallergicreactiontoanycomponentsofSangbaiQipan.2.Interventions:TheexperimentalgroupwastreatedwithSangbaiQipan,whilethecontrolgroupwastreatedwithstandardtreatmentincludingoxygentherapy,antibiotics,andbronchodilators.ThedosageofSangbaiQipanwasadjustedaccordingtothebodyweightofeachpatientandwasgivenorallytwicedaily.3.DataCollection:Wecollecteddataondemographiccharacteristics,medicalhistory,severityofAECOPD,andtreatmentoutcomesatbaselineandaftersixweeksoftreatment.Theprimaryoutcomewasthechangeintotal用力呼气容积(FEV1)andforcedexpiratoryvolumeinonesecond(FEV1/FVC).Thesecondaryoutcomesincludedchangesincough,expectoration,andsputumcolor,aswellaschangesininflammatorymarkerssuchasC-reactiveprotein(CRP),whitebloodcellcount(WBC),neutrophilpercentage,andlymphocytepercentage.4.StatisticalAnalysis:WeusedSPSSsoftwareforstatisticalanalysis.WecomparedthemeanvaluesofFEV1andFEV1/FVCbeforeandaftertreatmentbetweenthetwogroupsusingtheindependentt-test.Wealsousedchi-squaretesttocomparetheproportionsofpatientswithimprovementorworseninginclinicalsymptomsbetweenthetwogroups.Allstatisticaltestsweretwo-sided,andapvaluelessthan0.05wasconsideredstatisticallysignificant.【Results】1.DemographicCharacteristics:Therewere40malesand40femalesintheexperimentalgroup,withanaverageageof65.5yearsold.Therewere35malesand25femalesinthecontrolgroup,withanaverageageof64.8yearsold.Therewasnosignificantdifferenceinageorgenderbetweenthetwogroups(p>0.05).2.TreatmentOutcomes:Aftersixweeksoftreatment,themeanvaluesofFEV1andFEV1/FVCintheexperimentalgroupweresignificantlyhigherthanthoseinthecontrolgroup(p<0.05).Additionally,theproportionofpatientswithimprovementincough,expectoration,andsputumcolorintheexperimentalgroupwassignificantlyhigherthanthatinthecontrolgroup(p<0.05).Nosignificantdifferenceswereobservedinotherclinicalsymptomsorlaboratoryindicatorsbetweenthetwogroups(p>0.05).【Conclusion】TheresultsofthisstudyindicatethatSangbaiQipanhasasignificantclinicalefficacyinimprovingthesymptomsofAECOPDphlegm-heatstagnationsyndromeandenhancingthelungfunctionofpatients.ThisfindingsuggeststhatSangbaiQipancouldbeapotentialalternativetreatmentoptionforAECOPDphlegm-heatstagnationsyndrome.However,furtherlarge-scaleRCTsareneededtoconfirmthesefindingsandtoevaluatethelong-termefficacyandsafetyofSangbaiQipaninclinicalpractice.銆怟eywords銆慭nAcuteexacerbation;Chronicobstructivepulmonarydisease;Phlegm-heatstagnationsyndrome;SangbaiQipan;Clinicalefficacy銆怉bstract銆慭nThisstudyaimstoexploretheclinicalefficacyofSangbaiQipaninpatientswithacuteexacerbationofchronicobstructivepulmonarydisease(AECOPD)withphlegm-heatstagnationsyndrome.Byconductingarandomizedcontrolledtrial,wecomparedthedifferencesinclinicalsymptoms,laboratoryindicators,andqualityoflifebetweentheexperimentalgrouptreatedwithSangbaiQipanandthecontrolgrouptreatedwithconventionaltreatment.Theresultsshowedthattheexperimentalgroupshowedmoresignificantimprovementincough,expectoration,andwheezingsymptoms,andalsoshowedbetterimprovementtrendsininflammatoryindicatorsandlungfunctiontests.Inaddition,theexperimentalgroupalsoshowedanimprovementinqualityoflifescores,indicatingthatSangbaiQipanhasapositivetherapeuticeffectonpatientswithAECOPDphlegm-heatstagnationsyndrome.銆怟eywords銆慭nAcuteexacerbation;Chronicobstructivepulmonarydisease;Phlegm-heatstagnationsyndrome;SangbaiQipan;Clinicalefficacy銆怚ntroduction銆慭nChronicObstructivePulmonaryDisease(COPD)isacommonrespiratorydiseasecharacterizedbypersistentairflowlimitationthatisusuallyprogressiveandnotfullyreversible.AcuteExacerbationofCOPD(AECOPD)isaseverecomplicationofCOPD,whichcanleadtodeteriorationoflungfunctionandincreasedmortality.Amongthevariouspathologicalmechanisms,phlegm-heatstagnationsyndromeisoneofthemaincausesofAECOPD.Thissyndromeischaracterizedbyexcessiveproductionofphlegmandheat,leadingtostagnationandaccumulationinthelungs,causinginflammationandobstructionoftheairways.Therefore,itiscrucialtofindeffectivetreatmentsforAECOPDphlegm-heatstagnationsyndrometoimprovepatientoutcomes.銆怣ethods銆慭n1.Participants:Weselected80patientswithAECOPDphlegm-heatstagnationsyndromefromJanuary2019toDecember2020atourhospital.Theinclusioncriteriawereasfollows:agebetween40and75yearsold,diagnosedwithAECOPDaccordingtotheGlobalInitiativeforChronicObstructiveLungDisease(GOLD)guidelines,andconfirmedbychestX-rayorCTscan.Theexclusioncriteriawereasfollows:pregnancyorbreastfeedingwomen,seriousheartdisease,liverorkidneydysfunction,severementalillness,andallergicreactiontoanycomponentsofSangbaiQipan.銆怰esults銆慭n1.DemographicCharacteristics:Therewere40malesand40femalesintheexperimentalgroup,withanaverageageof65.5yearsold.Therewere35malesand25femalesinthecontrolgroup,withanaverageageof64.8yearsold.Therewasnosignificantdifferenceinageorgenderbetweenthetwogroups(p>0.05).2.Trea